Overall, these findings are in accordance with the poor response individuals with APLAID have to treatments that block interleukin-1, JAK1/2 or tumor necrosis factor. Here, JAK1 is linked to autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.